Patisiran-LNP Pregnancy Surveillance Program
Latest Information Update: 26 Sep 2024
Price :
$35 *
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloid polyneuropathy; Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 15 Sep 2021 New trial record